R&D | March 28, 2026
AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
Alkem’s semaglutide comes in a pre-filled disposable injection pen containing four doses for a month, priced at Rs. 1,800
The company plans to submit the vaccine for regulatory review
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
Subscribe To Our Newsletter & Stay Updated
